JIMRO Co., Ltd. (Gunma, Japan) developed the Adacolumn as the world’s first selective granulocyte and monocyte/macrophage apheresis system. The selectivity of the Adacolumn ensures that the regulatory T lymphocytes are spared for healthy immune function. The Adacolumn is filled with specially designed cellulose acetate beads as adsorptive carriers for therapeutic depletion of elevated/activated granulocytes, monocytes/macrophages together with a small fraction of lymphocytes (FcγR and complement receptors bearing leucocytes). The carriers also adsorb a significant fraction of platelets from the blood, which passes through the column. In Japan, the Adacolumn is approved and reimbursed by the Japan Ministry of Health, Labour and Welfare for the treatment of patients with ulcerative colitis, Crohn’s disease and pustular psoriasis. Likewise, the Adacolumn is CE-Marked (validated) by TUV of Germany for rheumatoid arthritis, ulcerative colitis, Crohn’s disease, ocular Behcet’s disease, systemic lupus erythematosus and pustular psoriasis. Accordingly in the EU countries, the Adacolumn is available for the treatment of these conditions. Our aspiration is to develop innovative products with the ultimate goal of providing effective treatment for debilitating refractory diseases worldwide.